{"preliminary_commentary":{"by_channel":{"youtube":2,"podcast":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"platinum pre-treated recurrent or metastatic nasopharyngeal cancer","name":"KEYNOTE-122","nct_id":"NCT02611960","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-122-nct02611960. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg Q3W for up to 17 cycles (up to approximately 1 additional year).","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive capecitabine 1000 mg/m\\^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle, or gemcitabine 1250 mg/m\\^2 IV on Days 1 and 8 of each 3-week cycle, or docetaxel 75 mg/m\\^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.","label":"Standard Treatment","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2022-09-30","type":"ACTUAL"},"conditions":["Nasopharyngeal Neoplasms"],"enrollment":{"count":233,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Capecitabine","otherNames":["XELODA®"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["GEMZAR®"],"type":"DRUG"},{"name":"Docetaxel","otherNames":["TAXOTERE®"],"type":"DRUG"}],"last_update":"2023-07-13","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-11-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 53 months (through analysis cut-off date of 30-Nov-2020)"}],"references":[{"citation":"Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol. 2023 Mar;34(3):251-261. doi: 10.1016/j.annonc.2022.12.007. Epub 2022 Dec 16.","pmid":"36535566","type":"RESULT"},{"citation":"Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Spreafico A, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Swaby RF, Wei B, Webber AL, Kang J, Gumuscu B, Yuan J, Siu LL. Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122. Cancer Med. 2026 Feb;15(2):e71496. doi: 10.1002/cam4.71496.","pmid":"41631899","type":"DERIVED"}],"start_date":{"date":"2016-04-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","url":"https://clinicaltrials.gov/study/NCT02611960"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-122-nct02611960"}